The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Optimal two-stage designs for phase II clinical trials.
Abstract
The primary objective of a phase II clinical trial of a new drug or regimen is to determine whether it has sufficient biological activity against the disease under study to warrant more extensive development. Such trials are often conducted in a multi-institution setting where designs of more than two stages are difficult to manage. This paper presents two-stage designs that are optimal in the sense that the expected sample size is minimized if the regimen has low activity subject to constraints upon the size of the type 1 and type 2 errors. Two-stage designs which minimize the maximum sample size are also determined. Optimum and "minimax" designs for a range of design parameters are tabulated. These designs can also be used for pilot studies of new regimens where toxicity is the endpoint of interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Simon’s minimax two-stage design31 is applied to test the MPR rate for each of the treatment arms.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311 · cited 1×
“Fleming's design is based on an approach developed for phase III trials [10] in which early rejection of a hypothesis occurs only when interim results are quite extreme.”
MethodOne-Sample Multiple Testing Procedure for Phase II Clinical Trials
Fleming, T. R. (1982) · Biometrics · doi:10.2307/2530297 · Cited by 1,003 · cited 2×
“Fleming [9] also studied k-stage designs with acceptance or rejection possible at each stage.”
BackgroundMethodGehan, E. A. (1961) · Journal of Chronic Diseases · doi:10.1016/0021-9681(61)90060-1 · Cited by 667
Biopharmaceutical Statistics for Drug Development.
Lamborn, K. R., & Peace, K. E. (1989) · Journal of the American Statistical Association · doi:10.2307/2289980 · Cited by 301
Predictive Probability Early Termination Plans For Phase II Clinical Trials
Herson, J. (1979) · Biometrics · doi:10.2307/2530109 · Cited by 140 · cited 1×
“Herson [12] described a multistage Bayesian approach in which the trial is terminated early if the predictive probability of rejecting the null hypothesis at the maximum sample size falls below a specified level.”
BackgroundDesigns for Group Sequential Phase II Clinical Trials
Chang, M. N., Therneau, T. M., Wieand, H. S., & Cha, S. S. (1987) · Biometrics · doi:10.2307/2531540 · Cited by 135 · cited 3×
“[14] for cases where the error probabilities are not too dissimilar.”
BackgroundMethodInfluentialJennison, C., & Turnbull, B. W. (1983) · Technometrics · doi:10.1080/00401706.1983.10487819 · Cited by 115 · cited 1×
“Jennison and Turnbull [6] and Chang and O'Brien [7] have described methods for calculating confidence intervals following sequential sampling procedures of the type proposed here.”
MethodBiopharmaceutical statistics for drug development
Metzler, C. M. (1988) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600770822 · Cited by 100
Confidence intervals following group sequential tests
Chang, M. N., & O’Brien, P. C. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90004-8 · Cited by 96 · cited 1×
“Jennison and Turnbull [6] and Chang and O'Brien [7] have described methods for calculating confidence intervals following sequential sampling procedures of the type proposed here.”
MethodMultiple-Stage Procedures for Drug Screening
Schultz, J. R., Nichol, F. R., Elfring, G. L., & Weed, S. D. (1973) · Biometrics · doi:10.2307/2529393 · Cited by 89
Cited by
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Metadata
- Authors
- Simon, R.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Simon, Richard
- ORCID
- Simon, Richard
- Venue
- Controlled Clinical Trials
- Publisher
- Elsevier BV
- Published
- 1989-03
- Volume
- 10
- Issue
- 1
- Pages
- 1-10
- ISSN
- 0197-2456 (ISSN-L)
- OpenAlex
- W2029409133
- Cited by
- 3,636
- References
- 16
- Citations by year
- 2026: 82 · 2025: 109 · 2024: 119 · 2023: 118 · 2022: 125 · 2021: 130 · 2020: 106 · 2019: 153 · 2018: 122 · 2017: 119 · 2016: 121 · 2015: 150 · 2014: 144 · 2013: 131 · 2012: 191
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Controlled Clinical Trials (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Management Science and Operations Research › Optimal Experimental Design Methods
- Physical Sciences › Mathematics › Statistics and Probability › Probability and Statistical Research
- Keywords
- two-stage design, optimal sample size, minimax design, pilot study, multi-institutional trial
- MeSH terms
- Drug Evaluation, Humans, Neoplasms, Research Design, Statistics as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimal two-stage designs for phase II clinical trials. https://app.cochat.ai/papers/10.1016/0197-2456(89)90015-9
- The paper
- Simon, R. (1989). Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials. https://doi.org/10.1016/0197-2456(89)90015-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.